The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
Open accessAbstract
JNK proteins have been shown to be involved in liver carcinogenesis in mice, but the extent of their involvement in the development of human liver cancers is unknown. Here, we show that activation of JNK1 but not JNK2 was increased in human primary hepatocellular carcinomas (HCCs). Further, JNK1 was required for human HCC cell proliferation in vitro and tumorigenesis after xenotransplantation. Importantly, mice lacking JNK1 displayed decreased tumor cell proliferation in a mouse model of liver carcinogenesis and decreased hepatocyte proliferation in a mouse model of liver regeneration. In both cases, impaired proliferation was caused by increased expression of p21, a cell-cycle inhibitor, and reduced expression of c-Myc, a negative regulator of p21. Genetic inactivation of p21 in JNK1-/- mice restored hepatocyte proliferation in models of both liver carcinogenesis and liver regeneration, and overexpression of c-Myc increased proliferation of JNK1-/- liver cells. Similarly, JNK1 was found to control the proliferation of human HCC cells by affecting p21 and c-Myc expression. Pharmacologic inhibition of JNK reduced the growth of both xenografted human HCC cells and chemically induced mouse liver cancers. These findings provide a mechanistic link between JNK activity and liver cell proliferation via p21 and c-Myc and suggest JNK targeting can be considered as a new therapeutic approach for HCC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
The JNK signal transduction pathway
Weston, C. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00258-1 · Cited by 1,528
Fausto, N., Campbell, J. S., & Riehle, K. J. (2006) · Hepatology · doi:10.1002/hep.20969 · Cited by 1,378
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Self-citationMammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update
Kyriakis, J. M., & Avruch, J. (2012) · Physiological Reviews · doi:10.1152/physrev.00028.2011 · Cited by 1,466
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Seki, E., Brenner, D. A., & Karin, M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.004 · Cited by 487
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yang, Y., Kim, S., & Seki, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676806 · Cited by 449
AP-1 — The Jun proteins: Oncogenes or tumor suppressors in disguise?
Shaulian, E. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.12.008 · Cited by 425
JNK at the crossroad of obesity, insulin resistance, and cell stress response
Solinas, G., & Becattini, B. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.12.001 · Cited by 422
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2019) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 381
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Chen, L., Park, S.-M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., Turner, J. R., Fu, Y.-X., Romero, I. L., Lengyel, E., et al. (2010) · Nature · doi:10.1038/nature09075 · Cited by 378
JNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
Kern, L., Mittenbühler, M., Vesting, A., Ostermann, A., Wunderlich, C., & Wunderlich, F. (2018) · Cancers · doi:10.3390/cancers11010024 · Cited by 331
“Hui and colleagues [65] reported that cancer cell proliferation decreases significantly in JNK1-deficient mice and that this reduction requires JNK-dependent p21 downregulation.”
Backgroundc-Jun N-terminal kinase (JNK) signaling: Recent advances and challenges
Bogoyevitch, M. A., Ngoei, K. R. W., Zhao, T. T., Yeap, Y. Y. C., & Ng, D. C. H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.002 · Cited by 323
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Adipose‐Derived Stem Cells for Tissue Engineering and Regenerative Medicine Applications
Dai, R., Wang, Z., Samanipour, R., Koo, K.-I., & Kim, K. (2016) · Stem Cells International · doi:10.1155/2016/6737345 · Cited by 301
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis
Inokuchi, S., Aoyama, T., Miura, K., Österreicher, C. H., Kodama, Y., Miyai, K., Akira, S., Brenner, D. A., & Seki, E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909781107 · Cited by 279
MAPK signaling in inflammation-associated cancer development
Huang, P., Han, J., & Hui, L. (2010) · Protein & Cell · doi:10.1007/s13238-010-0019-9 · Cited by 273
Self-citationModulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition
Kluwe, J., Pradere, J., Gwak, G., Mencin, A., De Minicis, S., Österreicher, C. H., Colmenero, J., Bataller, R., & Schwabe, R. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.015 · Cited by 217
Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209
“(26) Diabetes promotes hepatocarcinogenesis through activation of inflammatory cascades with production of proinflammatory cytokines and reactive oxygen species, which cause genomic instability, promote cellular proliferation, and inhibit apoptosis of hepatocytes.(27-33) Diabetes may also be associated with hyperinsul…”
BackgroundAjuba Family Proteins Link JNK to Hippo Signaling
Sun, G., & Irvine, K. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004324 · Cited by 153
Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathways
Papa, S., Bubici, C., Zazzeroni, F., & Franzoso, G. (2009) · bchm · doi:10.1515/bc.2009.111 · Cited by 156
“Consistent with these findings, recent studies in jnk1-/- and jnk2-/- mice challenged with DEN revealed that the JNK1 pathway has a dual stage-dependent function in HCC: one in the early stages of carcinogenesis in mediating DEN-induced PCD and the other in late stages, when it promotes the compensatory proliferation…”
Role of JNK signaling in oral cancer: A mini review
Gkouveris, I., & Nikitakis, N. G. (2017) · Tumor Biology · doi:10.1177/1010428317711659 · Cited by 87
Nakagawa, H., Hirata, Y., Takeda, K., Hayakawa, Y., Sato, T., Kinoshita, H., Sakamoto, K., Nakata, W., Hikiba, Y., Omata, M., et al. (2011) · Hepatology · doi:10.1002/hep.24357 · Cited by 86
Guma, M., Rius, J., Duong-Polk, K. X., Haddad, G. G., Lindsey, J. D., & Karin, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902659106 · Cited by 80
JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity
Enomoto, M., Kizawa, D., Ohsawa, S., & Igaki, T. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.05.001 · Cited by 74
Metadata
- Authors
- Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., & Wagner, E. F.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-12-01
- Volume
- 118
- Issue
- 12
- Pages
- 3943-3953
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2019953132
- Cited by
- 307
- References
- 50
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.